A Newborn with Teratogenic Effect of Imatinib Mesylate: A Very Rare Case Report

OBJECTIVE: To report a case of teratogenic effect of imatinib mesylate (IM) in a newborn, whose mother was suffering from chronic myelogenous leukemia and was treated with IM for 4 years, including during her pregnancy. CASE PRESENTATION AND INTERVENTION: The newborn was diagnosed with microtia of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Namita, Sharma, Deepak, Agrawal, Renu, Jain, Adeesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588294/
https://www.ncbi.nlm.nih.gov/pubmed/25896670
http://dx.doi.org/10.1159/000381806
Descripción
Sumario:OBJECTIVE: To report a case of teratogenic effect of imatinib mesylate (IM) in a newborn, whose mother was suffering from chronic myelogenous leukemia and was treated with IM for 4 years, including during her pregnancy. CASE PRESENTATION AND INTERVENTION: The newborn was diagnosed with microtia of the right ear, preauricular tag on the left side, absence of right depressor angular oris muscle, and imperforate anus. Infantogram showed dextrocardia, hemivertebrae in the thoracic region and cervical spina bifida occulta. The newborn was operated on for the imperforate anus and was discharged in good condition. CONCLUSION: This case revealed that IM is not safe for the fetus and leads to teratogenicity. Hence, we recommend that pregnant women should not be treated with IM.

Ejemplares similares